MX2008014679A - Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry. - Google Patents

Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.

Info

Publication number
MX2008014679A
MX2008014679A MX2008014679A MX2008014679A MX2008014679A MX 2008014679 A MX2008014679 A MX 2008014679A MX 2008014679 A MX2008014679 A MX 2008014679A MX 2008014679 A MX2008014679 A MX 2008014679A MX 2008014679 A MX2008014679 A MX 2008014679A
Authority
MX
Mexico
Prior art keywords
diagnosing
assays
fabry disease
treatment options
evaluating treatment
Prior art date
Application number
MX2008014679A
Other languages
English (en)
Inventor
Christine Kaneski
Sang-Hoon Shin
Gary Murray
Karin Ludwig
David Lockhart
Jeff Castelli
Original Assignee
Amicus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008014679(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc
Publication of MX2008014679A publication Critical patent/MX2008014679A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Ecology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan métodos in vitro e in vivo para determinar si un paciente con enfermedad de Fabry responderá al tratamiento con un chaperón farmacológico específico.
MX2008014679A 2006-05-16 2007-05-16 Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry. MX2008014679A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80108906P 2006-05-16 2006-05-16
US85363106P 2006-10-23 2006-10-23
PCT/US2007/069046 WO2007137072A2 (en) 2006-05-16 2007-05-16 Assays for diagnosing and evaluating treatment options for fabry disease

Publications (1)

Publication Number Publication Date
MX2008014679A true MX2008014679A (es) 2009-04-14

Family

ID=38723987

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2008014679A MX2008014679A (es) 2006-05-16 2007-05-16 Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
MX2013006681A MX351004B (es) 2006-05-16 2007-05-16 Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013006681A MX351004B (es) 2006-05-16 2007-05-16 Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.

Country Status (18)

Country Link
US (9) US7851143B2 (es)
EP (5) EP2024745B1 (es)
JP (6) JP2009537149A (es)
AU (1) AU2007253900A1 (es)
CA (1) CA2652553C (es)
CY (3) CY1115180T1 (es)
DK (2) DK2787345T3 (es)
ES (3) ES2573498T3 (es)
HK (3) HK1129458A1 (es)
HU (2) HUE027569T2 (es)
LT (1) LTC2787345I2 (es)
LU (1) LU93312I2 (es)
MX (2) MX2008014679A (es)
NL (1) NL300843I2 (es)
PL (2) PL2533050T6 (es)
PT (1) PT2533050E (es)
SI (2) SI2533050T1 (es)
WO (1) WO2007137072A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008014679A (es) 2006-05-16 2009-04-14 Amicus Therapeutics Inc Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
AU2008245578A1 (en) * 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US20110152319A1 (en) * 2008-02-12 2011-06-23 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
EP3470077B1 (en) * 2008-02-12 2020-08-26 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2009114712A2 (en) * 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for pompe disease
CA2781277C (en) * 2009-11-17 2018-01-09 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
US20110217288A1 (en) * 2010-03-05 2011-09-08 Baylor Research Institute Involvement of Androgen/Androgen Receptor Pathway in Fabry Disease
EP3698792A1 (en) * 2011-03-11 2020-08-26 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
EP3552664A1 (en) 2011-05-12 2019-10-16 Proteostasis Therapeutics, Inc. Proteostasis regulators
AU2012359165A1 (en) * 2011-12-22 2014-07-10 Centogene Ip Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
JP2015504919A (ja) 2012-01-25 2015-02-16 プロテオステイシス セラピューティクス，インコーポレイテッド プロテアソーム活性を調節する化合物
WO2014127038A1 (en) * 2013-02-12 2014-08-21 Baylor Research Institute Methods and compositions related to calcium homeostasis and fabry disease
ES2732308T3 (es) * 2013-12-23 2019-11-21 Bcn Peptides Sa Análogos de bicalutamida o (s)-bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
CN107074971B (zh) 2014-07-25 2021-11-02 夏尔人类遗传性治疗公司 人4-磷酸衔接蛋白2糖脂转移蛋白样域的晶体结构
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US20190183869A1 (en) * 2016-07-19 2019-06-20 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
US11335461B1 (en) 2017-03-06 2022-05-17 Cerner Innovation, Inc. Predicting glycogen storage diseases (Pompe disease) and decision support
CA3224537A1 (en) 2017-05-30 2018-12-06 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
CN111278438A (zh) * 2017-05-30 2020-06-12 阿米库斯治疗学公司 治疗具有肾损害的法布里患者的方法
US11923048B1 (en) 2017-10-03 2024-03-05 Cerner Innovation, Inc. Determining mucopolysaccharidoses and decision support tool
EP3749307A1 (en) 2018-02-06 2020-12-16 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
WO2019157056A1 (en) * 2018-02-06 2019-08-15 Amicus Therapeutics, Inc. Treatment of patients with classic fabry disease
JP2021530465A (ja) 2018-06-27 2021-11-11 プロテオステイシス セラピューティクス， インコーポレイテッド プロテアソーム活性増強化合物
CA3103954A1 (en) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
WO2020023390A1 (en) 2018-07-25 2020-01-30 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
JP2021024864A (ja) 2019-08-07 2021-02-22 アミカス セラピューティックス インコーポレイテッド Ｇｌａ遺伝子に突然変異を有する患者のファブリー病を治療する方法
US11191827B1 (en) * 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0463109A4 (en) * 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
WO1992000277A1 (fr) * 1990-06-29 1992-01-09 Nippon Shinyaku Co., Ltd. Derive de piperidine
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
EP0959877A4 (en) 1996-04-10 2000-08-23 Univ California CORRECTION OF GENETIC DEFECTS USING CHEMICAL CAPS
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
EP2857036B1 (en) 2003-01-31 2016-12-21 Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
EP1633356A1 (en) * 2003-05-22 2006-03-15 The Hospital for Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
CN1901907A (zh) 2003-11-12 2007-01-24 阿米库斯治疗学公司 用于治疗戈谢病的葡糖并咪唑和多羟基环己烯基胺衍生物
BRPI0612928A2 (pt) 2005-05-17 2010-12-07 Amicus Therapeutics Inc Método para aumentar a atividade de uma enzima de (alfa)-glucosidade em uma célula e método para tratar doença de pompe
US7973157B2 (en) 2005-06-08 2011-07-05 Amicus Therapeutics, Inc. Imino and amino sugar purification
EP1888068B1 (en) 2005-06-08 2014-05-21 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
CA2616537A1 (en) 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
WO2007089591A2 (en) 2006-01-27 2007-08-09 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for high throughput screening of pharmacological chaperones
MX2008014679A (es) 2006-05-16 2009-04-14 Amicus Therapeutics Inc Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
UA94624C2 (uk) 2006-09-22 2011-05-25 Крка, Товарна Здравіл, Д.Д., Ново Мєсто Арипіпразолу геміфумарат і спосіб його одержання
MX2009010557A (es) 2007-03-30 2009-11-19 Amicus Therapeutics Inc Metodo para el tratamiento de la enfermedad de fabry que utiliza chaperonas farmacologicas.
AU2008245578A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US20110152319A1 (en) 2008-02-12 2011-06-23 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
EP3470077B1 (en) 2008-02-12 2020-08-26 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
WO2010048532A1 (en) 2008-10-24 2010-04-29 Amicus Therapeutics, Inc. Multiple compartment dosing model
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US20110070643A1 (en) 2009-05-26 2011-03-24 Do Hung V Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
CA2781277C (en) 2009-11-17 2018-01-09 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
EP3698792A1 (en) 2011-03-11 2020-08-26 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
EP2874648A4 (en) 2012-07-17 2015-12-30 Amicus Therapeutics Inc CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN
JP7098529B2 (ja) 2016-03-22 2022-07-11 アミカス セラピューティックス インコーポレイテッド Ｇｌａ遺伝子にｇ９３３１ａ変異を有する患者においてファブリー病を処置する方法
US20190183869A1 (en) 2016-07-19 2019-06-20 Amicus Therapeutics, Inc. Treatment of fabry disease in ert-naïve and ert-experienced patients
JP2020503900A (ja) 2017-01-10 2020-02-06 アミカス セラピューティックス インコーポレイテッド ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ
CA3224537A1 (en) 2017-05-30 2018-12-06 Amicus Therapeutics, Inc. Methods of treating fabry patients having renal impairment
WO2019017938A1 (en) 2017-07-19 2019-01-24 Amicus Therapeutics, Inc. TREATMENT OF FABRY'S DISEASE IN PATIENTS WITHOUT SUBSTITUTED ENZYMATIC THERAPY (TES) AND PATIENTS SUBJECT TO TES
EP4176877A1 (en) 2017-08-28 2023-05-10 Amicus Therapeutics, Inc. Methods of enhancing and/or stabilizing cardiac function in patients with fabry disease
EP3749307A1 (en) 2018-02-06 2020-12-16 Amicus Therapeutics, Inc. Use of migalastat for treating fabry disease in pregnant patients
WO2019157056A1 (en) 2018-02-06 2019-08-15 Amicus Therapeutics, Inc. Treatment of patients with classic fabry disease
EP4285991A3 (en) 2018-08-20 2024-02-21 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
TW202112372A (zh) 2019-06-11 2021-04-01 美商阿米庫斯醫療股份有限公司 治療具有腎損害患者的Fabry氏病之方法
JP2021024864A (ja) 2019-08-07 2021-02-22 アミカス セラピューティックス インコーポレイテッド Ｇｌａ遺伝子に突然変異を有する患者のファブリー病を治療する方法

Also Published As

Publication number Publication date
HUE027569T2 (en) 2016-10-28
US10383864B2 (en) 2019-08-20
HK1129458A1 (en) 2009-11-27
EP2533050B1 (en) 2014-03-12
EP2955520B1 (en) 2018-10-31
JP2013100307A (ja) 2013-05-23
CY1117656T1 (el) 2017-05-17
US20170042868A1 (en) 2017-02-16
US20220160690A1 (en) 2022-05-26
LTPA2016033I1 (lt) 2016-12-12
US20150238474A1 (en) 2015-08-27
US20180250279A1 (en) 2018-09-06
JP7175297B2 (ja) 2022-11-18
JP2016006088A (ja) 2016-01-14
DK2787345T3 (en) 2016-05-30
ES2464527T3 (es) 2014-06-03
US9987263B2 (en) 2018-06-05
US11241422B2 (en) 2022-02-08
EP2533050A1 (en) 2012-12-12
US10406143B2 (en) 2019-09-10
JP6800176B2 (ja) 2020-12-16
PL2533050T6 (pl) 2016-05-31
EP2024745A2 (en) 2009-02-18
EP2787345A1 (en) 2014-10-08
PL2533050T3 (pl) 2014-08-29
EP2533050B3 (en) 2015-06-24
WO2007137072A3 (en) 2008-10-16
HUS1600048I1 (hu) 2017-01-30
EP2024745A4 (en) 2010-03-17
US20110104727A1 (en) 2011-05-05
LU93312I2 (fr) 2017-01-26
ES2573498T3 (es) 2016-06-08
US9000011B2 (en) 2015-04-07
EP2024745B1 (en) 2015-07-08
CY2016040I1 (el) 2017-06-28
PL2787345T3 (pl) 2016-08-31
JP2009537149A (ja) 2009-10-29
US20190388409A1 (en) 2019-12-26
ES2709445T3 (es) 2019-04-16
MX351004B (es) 2017-09-26
US9480682B2 (en) 2016-11-01
EP3457135A1 (en) 2019-03-20
NL300843I2 (es) 2016-12-21
HK1178975A1 (en) 2013-09-19
JP2020196717A (ja) 2020-12-10
ES2464527T7 (es) 2015-09-14
LTC2787345I2 (lt) 2017-10-10
SI2533050T1 (sl) 2014-07-31
DK2533050T6 (da) 2015-09-21
CY1115180T1 (el) 2016-12-14
EP2787345B8 (en) 2016-04-13
EP2955520A1 (en) 2015-12-16
CA2652553C (en) 2020-08-18
JP2023027053A (ja) 2023-03-01
AU2007253900A1 (en) 2007-11-29
WO2007137072A2 (en) 2007-11-29
HK1218955A1 (zh) 2017-03-17
JP2018138564A (ja) 2018-09-06
CY2016040I2 (el) 2017-06-28
US7851143B2 (en) 2010-12-14
US20080056994A1 (en) 2008-03-06
PT2533050E (pt) 2014-05-26
US20180325881A1 (en) 2018-11-15
DK2533050T3 (da) 2014-06-02
US20120220632A1 (en) 2012-08-30
EP2787345B1 (en) 2016-02-24
ES2464527T9 (es) 2015-07-24
JP6026268B2 (ja) 2016-11-16
SI2787345T1 (sl) 2016-08-31
CA2652553A1 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
MX2008014679A (es) Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de fabry.
WO2009114712A3 (en) Assays for diagnosing and evaluating treatment options for pompe disease
MX2010008835A (es) Metodo para predecir respuesta al tratamiento farmacologico con chaperona de enfermedades.
GB2467704A (en) Methods of monitoring conditions by sequence analysis
ES2530843T3 (es) Métodos basados en microARN para el diagnóstico de cáncer de páncreas
ZA200707425B (en) A method, device and system for volumetric enumeration of white blood cells
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
MX2010000139A (es) Detector de alcohol para la boca.
IL185501A0 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
MX2010005281A (es) Biomarcadores de diagnostico de diabetes.
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
EP3284469A3 (en) Compositions and methods for detection of lysosomal storage disease
GB0516145D0 (en) In vitro diagnostic kit for identification of human papillomavirus in clinical samples
MX2010005057A (es) Metodos y composiciones para uso de diagnostico en pacientes de cancer.
TWM371529U (en) Blood pressure monitor
EP1870710A4 (en) BIOMARKERS FOR DIAGNOSIS OF DISEASE AND USE THEREOF
WO2010133881A3 (en) Tissue analysis
EA201170613A1 (ru) ПРИМЕНЕНИЕ 7-ХЛОР-N,N,5-ТРИМЕТИЛ-4-ОКСО-3-ФЕНИЛ-3,5-ДИГИДРО-4Н-ПИРИДАЗИН[4,5-b]ИНДОЛ-1-АЦЕТАМИДА В КАЧЕСТВЕ БИОМАРКЕРА УРОВНЕЙ ПЕРИФЕРИЧЕСКОГО БЕНЗОДИАЗЕПИНОВОГО РЕЦЕПТОРА
WO2008099608A1 (ja) 炎症性腸疾患の診断方法
CA118203S (en) Straw chopper
WO2008119858A8 (es) Método in vitro no invasivo para detectar carcinoma transicional de vejiga
IN2012DN02711A (es)
UA38719U (ru) Способ диагностики инсулинорезистентности у больных артериальной гипертензией
UA46560U (ru) Способ диагностики клинического варианта метаболического синдрома

Legal Events

Date Code Title Description
FG Grant or registration